Dr. Andrea Apolo

So even if they progressed on checkpoint, continuing checkpoint and giving the infortimavidotin with pembrolizumab in the metastatic setting. So I am doing that. I don't think it's wrong just to give EV by itself, but I don't know what the right

So even if they progressed on checkpoint, continuing checkpoint and giving the infortimavidotin with pembrolizumab in the metastatic setting. So I am doing that. I don't think it's wrong just to give EV by itself, but I don't know what the right

And whether we continue the checkpoint inhibitor or not, there is data in kidney cancer where there is no benefit to continuing a checkpoint inhibitor once a patient has progressed on it. But most of it has been done in the metastatic setting, although the most recent data with Tivolumab was done a little bit earlier.

And whether we continue the checkpoint inhibitor or not, there is data in kidney cancer where there is no benefit to continuing a checkpoint inhibitor once a patient has progressed on it. But most of it has been done in the metastatic setting, although the most recent data with Tivolumab was done a little bit earlier.

And whether we continue the checkpoint inhibitor or not, there is data in kidney cancer where there is no benefit to continuing a checkpoint inhibitor once a patient has progressed on it. But most of it has been done in the metastatic setting, although the most recent data with Tivolumab was done a little bit earlier.

It did have some patients that had received adjuvant therapy, but a small number. And they did not see a benefit to continuing checkpoints. So I think this is an unanswered question. All cancers behave differently, have a different biology. We know that bladder cancer is not kidney cancer. So I think we need to answer this question prospectively.

It did have some patients that had received adjuvant therapy, but a small number. And they did not see a benefit to continuing checkpoints. So I think this is an unanswered question. All cancers behave differently, have a different biology. We know that bladder cancer is not kidney cancer. So I think we need to answer this question prospectively.

It did have some patients that had received adjuvant therapy, but a small number. And they did not see a benefit to continuing checkpoints. So I think this is an unanswered question. All cancers behave differently, have a different biology. We know that bladder cancer is not kidney cancer. So I think we need to answer this question prospectively.

And for now, if the patient can tolerate it, I do continue the checkpoint if they develop metastatic disease with and for Tamavidotin.

And for now, if the patient can tolerate it, I do continue the checkpoint if they develop metastatic disease with and for Tamavidotin.

And for now, if the patient can tolerate it, I do continue the checkpoint if they develop metastatic disease with and for Tamavidotin.

Yeah, I'm actually excited about the TAR system. The TAR 200 is with gemcitabine. But I'm excited about the whole device and the way that you can deliver it into the bladder so easily. And it delivers a slow amount of drug into the bladder. I love that. And the possibility that you can put other active therapies in there. So I'm really excited about it. And I think we do need...

Yeah, I'm actually excited about the TAR system. The TAR 200 is with gemcitabine. But I'm excited about the whole device and the way that you can deliver it into the bladder so easily. And it delivers a slow amount of drug into the bladder. I love that. And the possibility that you can put other active therapies in there. So I'm really excited about it. And I think we do need...

Yeah, I'm actually excited about the TAR system. The TAR 200 is with gemcitabine. But I'm excited about the whole device and the way that you can deliver it into the bladder so easily. And it delivers a slow amount of drug into the bladder. I love that. And the possibility that you can put other active therapies in there. So I'm really excited about it. And I think we do need...

something that kind of manages the bladder, right? So we have these great systemic therapies, but although most patients when they're responding to systemic therapies also respond within the bladder, it'd be nice to have an additional intensification of treatment in the bladder potentially in the future to have bladder sparing approaches.

something that kind of manages the bladder, right? So we have these great systemic therapies, but although most patients when they're responding to systemic therapies also respond within the bladder, it'd be nice to have an additional intensification of treatment in the bladder potentially in the future to have bladder sparing approaches.

something that kind of manages the bladder, right? So we have these great systemic therapies, but although most patients when they're responding to systemic therapies also respond within the bladder, it'd be nice to have an additional intensification of treatment in the bladder potentially in the future to have bladder sparing approaches.

And this may be a way of doing it, intensifying treatment with these tar systems and then leaving the bladder intact potentially.

And this may be a way of doing it, intensifying treatment with these tar systems and then leaving the bladder intact potentially.

And this may be a way of doing it, intensifying treatment with these tar systems and then leaving the bladder intact potentially.